Gastrointestinal Cancer

GPC3 has the potential to be targeted in patients with HCC with reduced off-target toxicities compared with other targeted agents.

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in September 2025.

The top 5 OncLive TV videos of the week cover insights in solid tumors, breast cancer, pancreatic cancer, and multiple myeloma.

Utidelone injection has received orphan drug designation by the FDA for the treatment of patients with pancreatic cancer.

Kohei Shitara, MD, discusses efficacy data from a trial of the CAR T-cell therapy satri-cel in advanced gastric/ GEJ adenocarcinoma and pancreatic cancer.

The FDA held a Type A meeting for RP1 in advanced melanoma, the AACR released its Annual Cancer Progress Report, and more.

Retifanlimab is the first and only immunotherapy agent to receive an indication for the frontline treatment of patients with advanced SCAC.

The NDA seeking approval of KN026 plus chemotherapy in HER2-positive gastric or GEJ cancer has been accepted for review in China.

The FDA approval of belzutifan in patients with pheochromocytoma or paraganglioma is a testament to the power of drug discovery in rare tumor subsets.

FDA grants type A meeting to discuss RP1 BLA in melanoma, CBP/p300 bromodomain inhibitor gets fast track status in NSCLC, and more.

Sanjiv Gangaram-Panday, PhD, discusses findings from a population-based cohort study of definitive chemoradiotherapy in esophageal adenocarcinoma.

The VENTANA HER2 (4B5) test earned CE-IVDR approval in Europe to assess HER2 status in metastatic breast cancer and biliary tract cancer.

Raji Shameem, MD, discusses considerations for selecting between available chemotherapy regimens for patients with advanced pancreatic cancer.

Samuel J. Klempner, MD, details the safety profile of givastomig/nivolumab and mFOLFOX6 in CLDN18.2-positive gastric, esophageal, and GEJ cancers.

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in August 2025.

The development of ZW171 for gynecologic, thoracic, and GI cancers is being discontinued.

Eric K. Singhi, MD, and Shruti Patel, MD, discuss how they extend beyond the walls of their clinic to provide accurate cancer updates on social media.

Adjuvant atezolizumab boosts survival in bladder cancer, FDA clears companion diagnostic for nivolumab doublet in MSI-H/dMMR colorectal cancer, and more.

The BRF14 study, which examined imatinib in patients with gastrointestinal stromal tumors, has the longest follow-up time in this sarcoma.

Zev A. Wainberg, MD, MSc, highlighted notable research in gastric cancer and cholangiocarcinoma presented during the 2025 ESMO GI Congress.

Nivolumab plus ipilimumab earned approval from Health Canada for select patients with unresectable colorectal cancer and hepatocellular carcinoma.

The FDA has received a premarket approval application supported by positive results from the PANOVA-3 trial for Tumor Treating Fields (TTFields)—electric fields that exert physical forces to kill cancer cells via a variety of mechanisms—for locally advanced pancreatic cancer.

The NMPA has granted breakthrough therapy designation to ATG-022 for previously treated gastric and gastroesophageal junction adenocarcinoma.

Tanios S. Bekaii-Saab, MD, discusses evolving frontline and evolving treatment strategies in esophageal cancer, HCC, and NETs.

Eileen M. O’Reilly, MD, discusses the potential of tumor treating fields for the treatment of patients with locally advanced pancreatic cancer.